Letter to Editor
Hydroxyethyl starch effects on tissue perfusion and oxygenation in patients undergoing liver surgery

Christian J Wiedermann

Department of Internal Medicine, Central Hospital of Bolzano, Bolzano (BZ), Italy
Received April 27, 2014; Accepted June 22, 2014; Epub June 15, 2014; Published June 30, 2014

In their recent report on the results of a clinical trial on effects of hydroxyethyl starch (HES) 130/0.4 and HES 200/0.5 on microcirculation perfusion and tissue oxygenation in patients undergoing liver surgery, Cui and co-workers [1] concluded that for patients undergoing major abdominal surgeries that entail a large amount of blood loss, using HES 130/0.4 for volume replacement treatment may have potential benefit in internal organ perfusion. In support of this conclusion, two studies from Boldt and co-workers have been cited (reference 3 and 4; reference 3 is cited a second time as reference 16) which have been retracted in 2011 because of scientific fraud [2, 3]. These citations and the misleading referencing need to be corrected.

Disclosure of conflict of interest

CJW has received fees for speaking at industry symposia from CSL Behring and Baxter.

Address correspondence to: Christian J Wiedermann, Department of Internal Medicine, Central Hospital of Bolzano, Lorenz-Böhler-Street 5, 39100 Bolzano, Bozen, BZ, Italy. Tel: +39 0471 908190; Fax: +39 0471 908303; E-mail: christian.wiedermann@asbz.it

References